Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amiodarone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 1.00 |
| ▸ | SIRT3 | Q9NTG7 | 7/20 | 1.00 |
| ▸ | KDM5A | P29375 | 7/20 | 1.00 |
| ▸ | THRA | P10827 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | KDM7A | Q6ZMT4 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | PHF2 | O75151 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amiodarone SCHEMBL5496372 | 1.00 | SIRT3 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL12487240 | 1.00 | SIRT3 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL16284 | 1.00 | SIRT3 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL41348 | 0.99 | ALDH1A1 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL29362650 | 0.99 | ALDH1A1 (1.00) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL29183902 | 0.99 | SIRT3 (0.98) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL29173757 | 0.99 | SIRT3 (0.98) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL28525007 | 0.99 | SIRT3 (0.98) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL19809514 | 0.98 | SIRT3 (0.96) | SIRT3KDM5ATHRATHRBALDH1A1 | |
| Amiodarone SCHEMBL28989964 | 0.98 | ALDH1A1 (0.98) | SIRT3KDM5ATHRATHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101534-A1 | MYOSTATIN AND ACTIVIN A IMMUNOGENS AND METHODS OF USE | VAXXINITY, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4026563-B1 | CONDITIONING PROTOCOLS AND USE OF SAME FOR TISSUE REGENERATION | YEDA RES & DEV (IL) | 2025-10-29 | — | — | EP | claimed |
| EP-4261235-B1 | BINDER COMPOUND AND METHOD FOR PREPARING SAME | CONTEMPORARY AMPEREX TECHNOLOGY HONG KONG LTD (HK) | 2025-10-01 | — | — | EP | claimed |
| EP-3515460-B1 | MACROPHAGE-BASED THERAPY FOR USE IN THE TREATMENT OF ACUTE LIVER INJURY | UNIV COURT UNIV OF EDINBURGH (GB) | 2025-09-17 | — | — | EP | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4011494-B1 | MICRO-NANOFLUIDIC CHIP, PREPARATION METHOD THEREFOR AND USE THEREOF | SHENZHEN INST ADV TECH (CN) | 2025-07-09 | — | — | EP | claimed |
| WO-2022253729-A1 | NEW THERAPEUTIC USE OF TYPE 2 IODOTHYRONINE DEIODINASE (D2) INHIBITORS | MATERIAS S.R.L. (IT) | 2022-12-08 | — | — | WO | claimed |
| CN-115275202-A | Slurry binder for lithium battery and preparation method and application thereof | 李凯强 | 2022-11-01 | — | — | CN | claimed |
| WO-2022214485-A1 | USE OF ANTI-CLOTTING COMPOUNDS AS RODENTICIDES | BIOROXX GMBH (DE) | 2022-10-13 | — | — | WO | claimed |
| EP-2991588-B1 | PROSTHETIC TISSUE VALVES | CORMATRIX CARDIOVASCULAR INC (US) | 2022-10-12 | — | — | EP | claimed |
| EP-4057999-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | Evonik Operations GmbH (DE) | 2022-09-21 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3753966-B1 | AMPHIPHILIC BLOCK COPOLYMER, PREPARATION METHOD THEREOF AND NANOMICELLE DRUG-LOADING SYSTEM | SHANGHAI BEST LINK BIOSCIENCE LLC (CN) | 2022-05-25 | — | — | EP | claimed |
| EP-3999043-A1 | PREPARATION OF LIPOPHILIC ACTIVE INGREDIENTS | SPI Pharma, INC. (US) | 2022-05-25 | — | — | EP | claimed |
| WO-2022102722-A1 | PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING CELL, CELL, METHOD FOR PRODUCING SURFACTANT PROTEIN, AND SCREENING METHOD | 国立大学法人京都大学 | 2022-05-19 | — | — | WO | claimed |
| EP-3253372-B1 | PREPARATION OF AN OIL-IN-WATER EMULSION FOR POLYMER STABILIZED PHARMACEUTICAL FORMULATIONS | SCHERER TECHNOLOGIES LLC R P (US) | 2022-04-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | SMPD3, SMPD4, CMA1 | KCNH2 1710/4885SIRT3 524/4885KDM5A 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.